Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C
Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)
The objective of this study is to evaluate the efficacy of three regimens of pegylated interferon-alfa 2b (PEG-IFN) either as monotherapy or in combination with ribavirin in participants with acute hepatitis C.
- Trial name
- NCT00686517
- Testing
- Pegylated interferon alfa-2b, Ribavirin
- Volunteers
- 130 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C
S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
This study will examine the effectiveness of S-adenosyl methionine (SAMe) in combination with peginterferon and ribavirin for treating hepatitis C virus.
- Trial name
- NCT00475176
- Testing
- Peginterferon alfa-2a, Ribavirin, S-adenosyl methionine for Chronic Liver Disease
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Anemia
A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.
This single arm study will assess the safety of NeoRecormon in the correction of anemia in patients with chronic hepatitis C who are being treated with Pegylated interferon + ribavirin combination therapy.
- Trial name
- NCT00560274
- Testing
- Pegasys, Ribavirin, epoetin beta [NeoRecormon]
- Where
- 24 sites in France
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis c, Metabolic Syndrome
Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir Combination
The purpose of the study is to determine if statin can affect the clinical outcome of chronic hepatitis C patients receiving Sofosbuvir/Daclatasvir/Ribavirin combination
- Trial name
- NCT03490097
- Testing
- Simvastatin 10mg, sofosbuvir plus daclatasvir
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Ain Shams University
Hepatitis C, Chronic
A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials
This open-label, non-randomized, single arm study will provide treatment or re-treatment with Pegasys (peginterferon alfa-2a) as monotherapy or in combination with Copegus (ribavirin) to patients with chronic hepatitis C…
- Trial name
- NCT01853254
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 272 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C
Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms
Chronic hepatitis C infection (HCV) is a disease that affects worldwide about 170 million people. The previous standard of care therapy of chronic HCV patients consists of pegylated-IFN-α combined with ribavirin, and results in…
- Trial name
- ETIM (NCT01641094)
- Where
- 2 sites in Netherlands
- Volunteers
- 20 people
- Sponsor
- Foundation for Liver Research
Hepatitis C, Chronic, Liver Diseases
Cellular Immune Responses in the Liver in Chronic Hepatitis C (CHC) Patients
In order to persist in the liver, HCV has numerous nonspecific and specific strategies to overcome the immunity of the host. The crucial step in the establishment of viral persistence and chronic hepatitis is the avoidance of…
- Conditions
- Hepatitis C, Chronic, Liver Diseases, Virus Diseases
- Trial name
- NCT01062659
- Where
- Germany
- Sponsor
- University of Ulm
Chronic Hepatitis C Infection
A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of response-guided duration of therapy with GS-9190 and GS-9256 in combination with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
- Trial name
- NCT01225380
- Testing
- GS-9190, GS-9256, Pegasys®
- Where
- 114 sites in United States, Austria and 9 more
- Volunteers
- 324 people
- Sponsor
- Gilead Sciences
Hepatitis C
Link Hepatitis C Notifications to Treatment in Tasmania
This project will utilise the notification process as a point of intervention to work with primary practitioners (GP) by contacting them directly when a notification of hepatitis C exposure is received by the Tasmanian department…
- Trial name
- NCT04510246
- Testing
- Enhanced case management
- Where
- Australia
- Volunteers
- 170 people, healthy volunteers welcome
- Sponsor
- Macfarlane Burnet Institute for Medical Research and Public Health Ltd
Hepatitis C Infection, Vitamin D Deficiency
Effects of Vitamin D on Inflammation in Liver Disease
Chronic liver diseases are associated with inflammation. The investigators postulate that Vitamin D may modulate inflammation. Thus the investigators will study the effect of Vitamin D replacement in patients with Hepatitis C…
- Trial name
- NCT01754961
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Veterans Medical Research Foundation
Hepatitis C
DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)
The purpose of the study is to examine whether patients who have acute or early chronic hepatitis C virus (HCV) infection can be treated effectively and safely with an interferon-sparing regimen that combines a new direct acting…
- Trial name
- DARE-C II (NCT02156570)
- Testing
- Sofosbuvir and ribavirin
- Where
- 5 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Kirby Institute
HEPATITIS C (HCV), Opioid Use Disorder
Pilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs
This study builds upon an ongoing NIH-funded randomized controlled trial (R01DA053325) evaluating a Partner Navigation Intervention to increase hepatitis C virus (HCV) treatment initiation among young adult people who inject…
- Conditions
- HEPATITIS C (HCV), Opioid Use Disorder, Substance Use Disorder (SUD), Drug Use Disorders
- Trial name
- NCT07631559
- Testing
- Partner navigation intervention booster session
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Hepatitis C, Hiv
Integrating HIV and Hepatitis C Screening in an Urban Emergency Department
This randomized controlled trial was implemented to evaluate the effect of integrating rapid Hepatitis C (HCV) testing into a pre-existing screening program for Human Immunodeficiency Virus (HIV) on HIV test acceptance and…
- Conditions
- Hepatitis C, Hiv, HIV/AIDS, HCV Coinfection
- Trial name
- NCT03252483
- Testing
- Bundled HCV/HIV Screening, HIV Screening
- Where
- United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- New York City Health and Hospitals Corporation
Hepatitis C, Chronic
Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan
To determine the treatment efficacy, safety and long-term outcomes of chronic hepatitis C patients receiving directly acting antivirals in Taiwan
- Trial name
- NCT03200379
- Testing
- directly acting antivirals (DAAs)
- Where
- Taiwan
- Volunteers
- 150,000 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Hepatitis C, Hepatitis B
Australian Hepatitis and Risk Survey in Prisons
The Australian Hepatitis and risk survey in prisons (AusHep) is a national prison-based blood-borne virus (BBV) surveillance study.
- Conditions
- Hepatitis C, Hepatitis B, HIV Infections
- Trial name
- AusHep (NCT05839522)
- Testing
- Point-of-care hepatitis C antibody test, Point-of-care hepatitis C RNA test, Point-of-care hepatitis B surface antibody test
- Where
- 24 sites in Australia
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Hepatitis C, Hepatitis C, Chronic
Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)
The objective of this study is to determine the relapse rate in the French patient population with chronic hepatitis C (CHC) previously treated with PegInterferon Alfa-2b (Peg-IFN alfa-2b) plus Ribavirin according to standard…
- Trial name
- RE-CHUT (NCT00725842)
- Testing
- Peg-IFN alfa-2b, Ribavirin
- Volunteers
- 97 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection
The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) + velpatasvir (VEL; GS-5816) with or without ribavirin (RBV) in treatment-naive adults with chronic…
- Trial name
- NCT01858766
- Testing
- SOF, VEL, RBV
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 379 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
Study of Nitazoxanide Combined With Peginterferon Compared to Peginterferon Monotherapy in the Treatment of Hepatitis C
The purpose of this study is to evaluate the safety and efficacy of nitazoxanide-peginterferon alfa-2b combination therapy compared to peginterferon monotherapy in patients that are treatment naive or pre-treated for 24 weeks…
- Trial name
- NCT00418054
- Testing
- Nitazoxanide plus peginterferon alfa-2b, Peginterferon alfa-2b
- Where
- 2 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Romark Laboratories L.C.
Chronic Hepatitis C
Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV
This is an extension of ongoing study SCI-SCV-HCV-P2-001 in which subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with…
- Trial name
- NCT01310205
- Testing
- SCV-07
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- SciClone Pharmaceuticals
Hepatitis C, Liver Diseases
Improving Hepatitis C Treatment in Injection Drug Users
The overall goal of the research project is to improve the outcome of medical care for injection drug users (IDUs) with Hepatitis C viral (HCV) infection.
- Conditions
- Hepatitis C, Liver Diseases, Drug Abuse, Alcoholism
- Trial name
- NCT00148031
- Testing
- Pegylated Interferon and Ribavirin, Psychosocial, On-site (MMT Clinic) HCV evaluation and treatment
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- State University of New York - Upstate Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.